Indication 'Carve In' Allowed Under Generic Labeling 'Carve-Out' Authority, US FDA Says

In citizen petition response involving Takeda's Velcade, agency says ANDA and 505(b)(2) applicants may add more words to the indication statement in order to carve-out protected uses from the reference product's broadly written indication.